on Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Announces Accelerated Path to EBITDA Positive

Stock price chart of Biotricity, Inc. (EBR:BTCY) showing fluctuations.

Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company in the remote cardiac monitor sector, has announced an accelerated timeline to achieving EBITDA positive. The company now anticipates reaching this milestone before the end of calendar 2024.

"Our strategic initiatives and technological advancements have put us on a fast track to profitability," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. The company reported a 25.2% increase in revenue in 2023, along with improvements in margins and a reduction in operating expenses.

Biotricity’s scaling capabilities, aided by its Cardiac AI Cloud platform and strategic partnerships, support this accelerated path. Health Canada’s approval for Biocore and partnerships with Group Purchasing Organizations are key to expanding market reach and driving revenue growth.

Targeting a $35 billion market opportunity, Biotricity solutions are used daily by cardiologists across 35 states, maintaining a high retention rate and strong recurring revenue base.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Biotricity, Inc. news